Warning: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) expects an increase in research and development expenses, projecting a decrease in annual profits by 52%-68%.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) issued a profit warning, forecasting that the net profit attributable to the parent company for the fiscal year 2024 will be between 35 million and 52 million yuan, a decrease of 52.1%-67.8% compared to the previous year. The reason is that the group is actively promoting the progress of R&D projects, with R&D expenses increasing by approximately 70 million yuan.

AASTOCKSJan 19 19:27

Fudan Zhangjiang 2024 Annual Results Forecast Announcement

SZSIJan 18 00:00 · Announcements

Fudan-Zhangjiang Bio-Pharma Expects Up to 68% Lower Net Profit in 2024

MT NewswiresJan 17 20:15

FUDANZHANGJIANG: INSIDE INFORMATION / PROFIT WARNING

HKEXJan 17 18:48 · Announcements

Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. expects its net income to decrease by 52.13% to 67.78% year-on-year in 2024.

BreakingsJan 17 18:07

Announcement Highlights | Wanwu Cloud acquires 100% equity of Zhongzhou Property; UBTECH executives commit not to reduce their Shareholding within 12 months.

C&D INTL GROUP: The cumulative contract sales amount for 2024 is about 103.36 billion yuan, a year-on-year decrease of about 25.1%; SHIMAO SERVICES plans to acquire 33% of Shenzhen Shilu Yuan Environmental for 83.159 million yuan for full ownership.

cls.cnJan 6 08:44